Frequent eye injections for diabetic retinal swelling
Part of Eyes & vision, Hormones & metabolism clinical trials.
This trial tests a more frequent dosing of an eye injection called pegaptanib (Macugen) to see if it can quickly reduce swelling in the retina caused by diabetes and improve vision. It is for people with diabetic macular edema who have some vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have type 1 or type 2 diabetes.
- Your vision in the study eye must be between 20/40 and 20/400 (this is considered moderate to severe vision loss).
- You need a diagnosis of diabetic macular edema, confirmed by eye scans and a special dye test.
- You cannot have had certain eye treatments recently: steroid injections within 3 months, other anti-VEGF injections within 2 months, or any eye surgery within 30 days.
- You must not have a history of stroke in the past year, severe heart disease, or significant kidney or liver problems.
- You should not have serious allergies to the dye used in the eye test or to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a single steroid injection around the back of the eye can improve vision in people with diabetic macular edema (swelling in the center of the retina that blurs vision). It is for people who have not yet had any other eye treatments for this condition.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
This study compares two different eye injection treatments for diabetic macular edema (DME)—a condition where fluid builds up in the center of the retina, blurring vision. Researchers want to see how certain measures in the blood and in eye scans relate to how well each treatment works.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This trial tests a gentle laser treatment (micropulse laser) to reduce swelling in the center of the retina caused by diabetes. The goal is to improve or protect your vision without the need for injections or stronger laser.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.